This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Reducing Glycemic Variability in Type 1 Diabetes: An Exploration of Non-Insulin Treatment Options

Reducing Glycemic Variability in Type 1 Diabetes: An Exploration of Non-Insulin Treatment Options

Format

Webcast

Time to Complete

1.50 hours

Released

January 10, 2019

Expires

January 10, 2020
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditTM
1.50 / CE for Nurses (0.70 pharmacotherapy credit)
1.50 / CE for Pharmacists
1.50 / CPEUs for Registered Dietitians

Joint Providers

Jointly provided by the Postgraduate Institute for Medicine and E&S MedEd Group

Commercial Supporter

Supported by an independent educational grant provided by Sanofi and Lexicon Pharmaceuticals.

Program Description

Clinicians may be unaware of outcomes from recent studies of GLP-1 RAs, DPP-4 inhibitors, and SGLT1 or SGLT2 inhibitors in T1DM. This program will include education on the causative factors and consequences of glycemic variability, and ways in which newer non-insulin glucose-lowering agents can help to prevent hyper- and hypoglycemia. As part of the program, the presentations will include case vignettes that demonstrate individualized care of people with T1DM.

Media

Internet

Intended Audience

This activity is intended for physicians, pharmacists, advanced practice nurses and certified diabetes educators engaged in the care of patients with Type 1 Diabetes.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Review the importance of achieving target A1C and the consequences of long-term hyperglycemia in people with T1DM
  • Describe how the mechanisms of action of newer non- insulin glucose-lowering agents differ from traditional insulin-based therapies
  • Summarize the risks and benefits associated with newer non-insulin glucose- lowering agents in T1DM
  • Identify people with T1DM in whom newer non-insulin glucose-lowering therapy may be appropriate

Conflict Of Interest Disclosure Policy

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Thomas Repas, DO, FACP, FACOI, FNLA, FACE, CDE (Course Director)
Endocrinology, Diabetes, and Metabolism
Clinical Lipidology
Nutrition; & Internal Medicine
Campbell County Health

Dr. Repas has disclosed the following:
Speakers’ Bureaus: Janssen Pharmaceuticals, Inc. and Sanofi Aventis

Linda B Haas, PhC, RN, Certified Diabetes Educator (ret)
Diabetes Consultant

Ms. Haas has nothing to disclose.

Susan Cornell, PharmD, CDE, FAPhA, FAADE
Associate Director of Experiential Education
Associate Professor of Pharmacy Practice Midwestern University
Diabetes Educator and Care Provider
Bolingbrook Christian Health Clinic
Will-Grundy Medical Clinic

Dr. Cornell has disclosed the following:
Speaker’s Bureau and Advanced Practitioner Advisory Board: Novo Nordisk

Curtis L. Triplitt, PharmD, CDE
Associate Director, Diabetes Research
Texas Diabetes Institute
Clinical Associate Professor
Department of Medicine
Division of Diabetes
University of Texas Health Science Center at San Antonio

Dr. Triplitt has disclosed the following:
Speakers’ Bureaus: AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Janssen

PLANNERS AND MANAGERS DISCLOSURES

The PIM planners and managers have nothing to disclose.
The AADE planners and managers have nothing to disclose.
The E&S MedEd Group planners and managers have nothing to disclose.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and E&S MedEd Group. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.50

Type

CE for Nurses

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and E&S MedEd Group. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.50 contact hours. Designated for 0.70 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Credit

1.50

Type

CE for Pharmacists

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and E&S MedEd Group. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Postgraduate Institute for Medicine designates this continuing education activity for 1.50 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-474-H01-P

Type of Activity : Knowledge

Credit

1.50

Type

CPEU Credit

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and E&S MedEd Group. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.50 Continuing Professional Education units (CPEUs) for completion of this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions

There are no fees for participating and receiving CME or CNE credit for this activity. During the period January 10, 2019 through January 10, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.

To obtain credit a score of 75% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue